Positively, based on current evidence. The SELECT trial showed semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in overweight/obese adults with existing heart disease. GLP-1 agonists also tend to lower blood pressure and improve lipid profiles. Mild heart rate increases (2-4 bpm) are common but generally not clinically significant. Overall, the cardiovascular data is one of the strongest arguments in favor of these medications beyond weight loss alone.